At the news
? NEUTRALIMPACT 2/10 144 filed Jun 22, 2026 at 16:09 ET
Myrtle S. Potter, a Director of Guardant Health, filed a Form 144 on 2026-06-22 to sell 1,556 shares of common stock, with an estimated aggregate market value of approximately $204,085. The shares were acquired via a restricted stock lapse on 2026-06-18, indicating this is a routine equity-compensation-related sale.
- Insider: Myrtle S. Potter, a Director of Guardant Health
- Proposed sale: 1,556 shares of common stock
- Estimated value: ~$204,085 (based on $132.60/share reference price)
- Shares acquired on 2026-06-18 via restricted stock lapse (equity compensation)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access